Satoh T, Yoshida G, Orito Y, Koike T
Osaka Municipal Kosaiin Hospital.
Nihon Rinsho. 1998 Mar;56(3):742-7.
The number of agents for the treatment of osteoporosis has increased over the past few years allowing more and more differentiated therapy. Calcitonin, vitamin D3, bisphosphonate, estrogen, vitamin K2 and calcium are administered for the treatment of osteoporosis in Japan. The purpose of drug delivery system (DDS) is to provide a practical approach to increasing efficacy and minimizing side effects of the drugs. In fact by the development of DDS, topical administration, prodrug and targeting therapy are used in the treatment for osteoporosis. It is well known that calcitonin in susceptible to proteolysis in the intestine. So, calcitonin must be given intramuscular or subcutaneous injection for therapy. DDS of calcitonins is studying in many routes of administration, such as nasal, transdermal, ocular, oral, bronchial, rectal and vaginal.
在过去几年中,用于治疗骨质疏松症的药物数量有所增加,从而使治疗方法越来越多样化。在日本,降钙素、维生素D3、双膦酸盐、雌激素、维生素K2和钙被用于治疗骨质疏松症。药物递送系统(DDS)的目的是提供一种切实可行的方法来提高药物疗效并将副作用降至最低。事实上,通过药物递送系统的发展,局部给药、前药和靶向治疗已被用于骨质疏松症的治疗。众所周知,降钙素在肠道中易受蛋白水解作用影响。因此,降钙素必须通过肌肉注射或皮下注射进行治疗。目前正在研究多种降钙素的给药途径,如鼻腔、透皮、眼部、口服、支气管、直肠和阴道给药。